Cassava Sciences Inc vs Target Corporation — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Target Corporation trades at $153.81 (market cap $70.31B). The key difference: Target Corporation is far larger — about 1784.5× Cassava Sciences Inc's market cap, and Target Corporation pays a 3% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Target Corporation for 137 Days on average.
| FLNA | TGT | |
|---|---|---|
Market Cap | $39.40M | $70.31B |
Volume | 759,018 | 4,164,999 |
Sector | Health | Consumer Staples |
52-Week High | $4.64 | $169.90 |
52-Week Low | $0.68 | $83.68 |
Typical Hold Time | 37 Days | 137 Days |
Enterprise Value | -$43.28M | $83.58B |
Dividend Yield | — | 3% |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
Target Corporation (TGT) trades at $154.56, up 2.38% with strong recent earnings beats and positive analyst sentiment. The stock shows bearish technical signals but maintains solid fundamentals with a 4.08% net margin and 26.41% ROE. Recent price cuts on 2,000 items aim to capture holiday market share, while consistent dividend payments reinforce shareholder returns. Valuation metrics appear reasonable with P/E of 16.05 and P/S of 0.65.
Target presents a balanced opportunity with analyst consensus pointing to 8% upside to the $167.18 price target. The turnaround strategy shows early success, but competitive pressures and margin compression from price investments remain key risks. Institutional support remains strong with 60 analyst coverage favoring buy/hold positions.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →